Please use this identifier to cite or link to this item:
|Title:||Effects of Angiotensin II Type I receptor blocker on bones in mice with Type I diabetes induced by Streptozotocin|
|Source:||Journal of the Renin-angiotensin-aldosterone system, 2014, v. 15, no. 3, p. 218-227 How to cite?|
|Journal:||Journal of the Renin-angiotensin-aldosterone system|
|Abstract:||Introduction: This study was performed to address the pathological roles of the skeletal renin-angiotensin system (RAS) in type 1 diabetes-induced osteoporosis and the effects of the angiotensin II type 1 receptor blocker losartan on bones in diabetic mice.|
Materials and methods: Bone histomorphology was detected by H&E staining, Safranin O staining and X-ray radiography. Micro-CT was performed for the analysis of bone parameters. Gene and protein expression were determined by RT-PCR and immunoblotting.
Results: Type 1 diabetic mice displayed osteopenia phenotype, and losartan treatment had no osteoprotective effects on diabetic mice as shown by the reduction of bone mineral density and microarchitectural parameters at the proximal metaphysis of the tibia. The mRNA expression of AGT, renin receptor and ACE, and protein expression of renin and AT1R were markedly up-regulated in the bones of vehicle-treated diabetic mice compared to those of non-diabetic mice. The treatment with losartan further significantly increased the expression of AGT, renin, angiotensin II and AT1R, and reduced the expression of AT2R receptor as compared to those of diabetic mice.
Conclusion: Local bone RAS functionally played a role in the development of type 1 diabetic osteoporosis, and losartan had no bone-sparing function in diabetes mice because of enhance skeletal RAS activity.
|Appears in Collections:||Journal/Magazine Article|
Show full item record
Citations as of Feb 19, 2017
WEB OF SCIENCETM
Citations as of Feb 22, 2017
Checked on Feb 26, 2017
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.